Ph3 Trial of trastuzumab deruxtecan minus pembro with mGEJ
Phase III Clinical Trial
A Multicenter randomized open label Phase 3 Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus Pembrolizumab versus chemotherapy plus Trastuzumab plus or minus Pembrolizumab as first line treatment in participants with unresectable locally advanced or metastatic HER2-postive Gastric or GEJ cancer. (Destiny- Gastric05) (Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus Pembrolizumab versus chemotherapy plus trastuzumab plus or minus Pembrolizumab in first line metastatic HER2-positive gastric or GEJ cancer) (DS8201-724)